[Anti-EGFR antibody therapy for colorectal cancer].
The epidermal growth factor receptor (EGFR) triggers a downstream signaling cascade such as the RAS-RAF-MAPK and PI3K-AKT pathways, which are involved in cell proliferation, differentiation, survival and invasion. Two monoclonal antibodies (moABS) targeting EGFR, cetuximab and panitumumab, are established to be a new treatment for metastatic colorectal cancers. Among activating mutations in the downstream of EGFR, the KRAS gene mutation has shown to be predictive biomarker for resistance to anti-EGFR antibody therapy. This review focuses on the current status of chemotherapy with anti-EGFR antibody for colorectal cancers. The identification of patients who are likely to benefit from EGFR-targeted moABS is increasingly crucial for improving therapeutic strategies.